{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:35:48Z","timestamp":1791516948813,"version":"4.3.4"},"reference-count":360,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A decade since immune checkpoint inhibitors made a stride in the clinical landscape of oncology, there has been a substantial focus on understanding the response heterogeneity following these therapies. Insights gained from clinical data identified the primary and secondary resistance mechanisms that escape the upfront therapy pressure. Beyond PD-1 and CTLA-4, new checkpoints averting this pressure are under clinical development. Adenosinergic pathways are actively engaged in oncogenic signaling. The main protagonists, CD73, A2AR, and A2BR, span diverse immune subsets of lymphoid and myeloid lineages and have emerged as alternative checkpoints. This review discusses the latest update on immune regulation dynamics of adenosine receptor signaling and their complex interplay with hypoxia in a heterogeneous tumor immune microenvironment (TIME). In this spectrum, we also review the plasticity of A2AR and A2BR in designing new drug candidates, tracing their complex metabolic roots in inducing immune dysfunction. Beyond the existing modalities, the ENT1 and MTAP-loss-MTA axis shows scope for alternative perturbations. The CD39-CD73-A2AR axis plays a central role in the terminal exhaustion of T cells. We highlight the interventions that disrupt the mechanistic context of A2AR and its cooperativity with other suppressors to restore anti-tumor immune functions following inhibition of their multilayered signaling. We capture the ongoing clinical trials and predictive biomarker landscape, along with novel delivery methods, to illustrate the evolving trends in this field. From these perspectives, we discuss how the adenosine axis can widen this new therapeutic avenue and boost the efficacy of CAR-T therapies. Therapeutic cancer vaccines are a new modality in this premise. Finally, an integrated overview of this pathway, along with TIME dynamics, illustrates the barriers and opportunities of combining adenosine signaling inhibitors in clinical trials.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1676702","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:32:22Z","timestamp":1767875542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Adenosine receptors on the immuno-oncology expressway: TIME, perspectives, and translation"],"prefix":"10.3389","volume":"16","author":[{"given":"Biswanath","family":"Majumder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santanu","family":"Datta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0031-6997(24)01511-4","article-title":"International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors","volume":"53","author":"Fredholm","year":"2001","journal-title":"Pharmacol Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.chemrev.6b00177","article-title":"GPCR dynamics: Structures in motion","volume":"117","author":"Latorraca","year":"2017","journal-title":"Chem Rev"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: The state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/nrd1983","article-title":"Adenosine receptors as therapeutic targets","volume":"5","author":"Jacobson","year":"2006","journal-title":"Nat Rev Drug Discov"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2010.12.006","article-title":"Pain-relieving prospects for adenosine receptors and ectonucleotidases","volume":"17","author":"Zylka","year":"2011","journal-title":"Trends Mol Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/aap.12037","article-title":"The terms \u2018autacoid\u2019, \u2018hormone\u2019 and \u2018chalone\u2019 and how they have shifted with time","volume":"35","author":"Keppel Hesselink","year":"2015","journal-title":"Auton Autacoid Pharmacol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2016.02.006","article-title":"Adenosine as a Multi-Signalling Guardian Angel in Human Diseases: When, Where and How Does it Exert its Protective Effects","volume":"37","author":"Borea","year":"2016","journal-title":"Trends Pharmacol Sci"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0382-2","article-title":"The adenosine pathway in immuno-oncology","volume":"17","author":"Allard","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114382","article-title":"Retrograde adenosine\/A2A receptor signaling facilitates excitatory synaptic transmission and seizures","volume":"43","author":"Nasrallah","year":"2024","journal-title":"Cell Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.115184","article-title":"Drugs targeting adenosine signaling pathways: A current view","volume":"165","author":"Kutryb-Zaj\u0105c","year":"2023","journal-title":"Biomed Pharmacother"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-020-09694-2","article-title":"The belated US FDA approval of the adenosine A2A receptor antagonist istradefylline for treatment of Parkinson\u2019s disease","volume":"16","author":"Chen","year":"2020","journal-title":"Purinergic Signal"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1258637","article-title":"Adenosine, bridging chronic inflammation and tumor growth","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1124\/mol.106.032920","article-title":"Caffeine inhibits adenosine-induced accumulation of hypoxia-inducible factor-1\u03b1, vascular endothelial growth factor, and interleukin-8 expression in hypoxic human colon cancer cells","volume":"72","author":"Merighi","year":"2007","journal-title":"Mol Pharmacol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.11.010","article-title":"Association between coffee intake after diagnosis of colorectal cancer and reduced mortality","volume":"154","author":"Hu","year":"2018","journal-title":"Gastroenterology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1126\/science.167434","article-title":"Adenosine inhibition of lymphocyte-mediated cytolysis: Possible role of cyclic adenosine monophosphate","volume":"187","author":"Wolberg","year":"1975","journal-title":"Science"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20160961","article-title":"Resetting microbiota by Lactobacillus reuteri inhibits T reg deficiency-induced autoimmunity via adenosine A2A receptors","volume":"214","author":"He","year":"2017","journal-title":"J Exp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0544","article-title":"Adenosine 2B receptor expression on cancer cells promotes metastasis","volume":"76","author":"Mittal","year":"2016","journal-title":"Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1146\/annurev-immunol-070621-030155","article-title":"Resistance mechanisms to anti-PD cancer immunotherapy","volume":"40","author":"Vesely","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-024752","article-title":"Beyond the barrier: unraveling the mechanisms of immunotherapy resistance","volume":"42","author":"Bell","year":"2024","journal-title":"Annu Rev Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1038\/414916a","article-title":"Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage","volume":"414","author":"Ohta","year":"2001","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0605251103","article-title":"A2A adenosine receptor protects tumors from antitumor T cells","volume":"103","author":"Ohta","year":"2006","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-014-1189-3","article-title":"Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1\u03b1-dependent and extracellular adenosine-mediated tumor protection","volume":"92","author":"Hatfield","year":"2014","journal-title":"J Mol Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0917-805","article-title":"Adenosine checkpoint agent blazes a trail, joins immunotherapy roster","volume":"35","author":"Garber","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade5111","article-title":"Hypoxia-inducible factor orchestrates adenosine metabolism to promote liver cancer development","volume":"9","author":"Cheu","year":"2023","journal-title":"Sci Adv"},{"key":"B25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41467-019-14060-x","article-title":"CD73 on cancer-associated fibroblasts enhanced by the A2B-mediated feedforward circuit enforces an immune checkpoint","volume":"11","author":"Yu","year":"2020","journal-title":"Nat Commun"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1038\/s41467-022-32430-w","article-title":"Single cell spatial analysis reveals the topology of immunomodulatory purinergic signaling in glioblastoma","volume":"13","author":"Coy","year":"2022","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ab.2018.11.004","article-title":"Development of a quantification method for adenosine in tumors by LC-MS\/MS with dansyl chloride derivatization","volume":"568","author":"Goodwin","year":"2019","journal-title":"Anal Biochem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0203-7","article-title":"Navigating metabolic pathways to enhance antitumour immunity and immunotherapy","volume":"16","author":"Li","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-sitc2023.0759","article-title":"759 ADPORT-601 (TT-10\u2013101): first-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in participants with selected advanced solid tumors","volume":"11","author":"Subudhi","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-018-0706-6","article-title":"Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers","volume":"37","author":"Seitz","year":"2019","journal-title":"Invest New Drugs"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e006457","DOI":"10.1136\/jitc-2022-006457","article-title":"Defining the spatial distribution of extracellular adenosine revealed a myeloid-dependent immunosuppressive microenvironment in pancreatic ductal adenocarcinoma","volume":"11","author":"Graziano","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-012-0988-7","article-title":"Transcriptional control of adenosine signaling by hypoxia-inducible transcription factors during ischemic or inflammatory disease","volume":"91","author":"Poth","year":"2013","journal-title":"J Mol Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/j.1748-1716.1991.tb09133.x","article-title":"Extracellular levels of adenosine and its metabolites in the striatum of awake rats: Inhibition of uptake and metabolism","volume":"142","author":"Ballarin","year":"1991","journal-title":"Acta Physiol Scand"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.1990.tb14097.x","article-title":"Effect of propentofylline (HWA 285) on extracellular purines and excitatory amino acids in CA1 of rat hippocampus during transient ischaemia","volume":"100","author":"Andine","year":"1990","journal-title":"Br J Pharmacol"},{"key":"B35","article-title":"The extracellular fluid of solid carcinomas contains immunosuppressive concentrations of adenosine","volume":"57","author":"Blay","year":"1997","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.0133-13.2013","article-title":"Tissue-nonspecific alkaline phosphatase acts redundantly with PAP and NT5E to generate adenosine in the dorsal spinal cord","volume":"33","author":"Street","year":"2013","journal-title":"J Neurosci"},{"key":"B37","doi-asserted-by":"publisher","first-page":"e26246","DOI":"10.4161\/onci.26246","article-title":"A CD38\/CD203A\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein","year":"2013","journal-title":"Oncoimmunology"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2013.03.005","article-title":"CD39 and CD73 in immunity and inflammation","volume":"19","author":"Antonioli","year":"2013","journal-title":"Trends Mol Med"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02153-3","article-title":"Inhibition of ENT1 relieves intracellular adenosine-mediated T\u2009cell suppression in cancer","volume":"26","author":"Sanders","year":"2025","journal-title":"Nat Immunol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"8260","DOI":"10.1038\/s41467-023-43917-5","article-title":"Single-cell spatial metabolomics with cell-type specific protein profiling for tissue systems biology","volume":"14","author":"Hu","year":"2023","journal-title":"Nat Commun"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059796","article-title":"Targeting of HIF-\u03b1 to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation","volume":"292","author":"Jaakkola","year":"2001","journal-title":"Science"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12673","article-title":"Structural basis for oxygen degradation domain selectivity of the HIF prolyl hydroxylases","volume":"7","author":"Chowdhury","year":"2016","journal-title":"Nat Commun"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203938","article-title":"Up-regulation of hypoxia-inducible factors HIF-1\u03b1 and HIF-2\u03b1 under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function","volume":"19","author":"Krieg","year":"2000","journal-title":"Oncogene"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.202102234","article-title":"Oxygen-generating cryogels restore T cell mediated cytotoxicity in hypoxic tumors","volume":"31","author":"Colombani","year":"2021","journal-title":"Adv Funct Mater"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e174675","DOI":"10.1172\/jci.insight.174675","article-title":"Oxygen-carrying nanoemulsions and respiratory hyperoxia eliminate tumor hypoxia-induced immunosuppression","volume":"10","author":"Halpin-Veszeleiova","year":"2025","journal-title":"JCI Insight"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1172\/JCI137554","article-title":"Antihypoxic oxygenation agents with respiratory hyperoxia to improve cancer immunotherapy","volume":"130","author":"Hatfield","year":"2020","journal-title":"J Clin Invest"},{"key":"B47","doi-asserted-by":"publisher","first-page":"10872","DOI":"10.1038\/s41467-024-55207-9","article-title":"An antibody cocktail targeting two different CD73 epitopes enhances enzyme inhibition and tumor control","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1124\/mol.104.007807","article-title":"Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin 1","volume":"67","author":"Desai","year":"2005","journal-title":"Mol Pharmacol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02843-x","article-title":"Increased expression of adenosine 2A receptors in metastatic renal cell carcinoma is associated with poorer response to anti-vascular endothelial growth factor agents and anti-PD-1\/Anti-CTLA4 antibodies and shorter survival","volume":"70","author":"Kamai","year":"2021","journal-title":"Cancer Immunol Immunother"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.46.3653","article-title":"Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers","volume":"31","author":"Jain","year":"2013","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1021\/acsnano.8b07865","article-title":"Dexamethasone increases cisplatin-loaded nanocarrier delivery and efficacy in metastatic breast cancer by normalizing the tumor microenvironment","volume":"13","author":"Martin","year":"2019","journal-title":"ACS Nano"},{"key":"B52","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4197","article-title":"Vessel co-option mediates resistance to anti-angiogenic therapy in liver metastases","volume":"22","author":"Frentzas","year":"2016","journal-title":"Nat Med"},{"key":"B54","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.ccell.2018.01.011","article-title":"Fibroblast heterogeneity and immunosuppressive environment in human breast cancer","volume":"33","author":"Costa","year":"2018","journal-title":"Cancer Cell"},{"key":"B55","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1084\/jem.20180870","article-title":"Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non-small cell lung cancer","volume":"216","author":"Gong","year":"2019","journal-title":"J Exp Med"},{"key":"B56","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12943-021-01490-9","article-title":"Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma","volume":"21","author":"Serrat\u00ec","year":"2022","journal-title":"Mol Cancer"},{"key":"B57","doi-asserted-by":"publisher","first-page":"5911","DOI":"10.1038\/s41467-021-26134-w","article-title":"CD73-mediated adenosine production by CD8 T cell-derived extracellular vesicles constitutes an intrinsic mechanism of immune suppression","volume":"12","author":"Schneider","year":"2021","journal-title":"Nat Commun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-0129-7","article-title":"Breast cancer-derived exosomes transmit lncRNA SNHG16 to induce CD73+\u03b3\u03b41 Treg cells","volume":"5","author":"Ni","year":"2020","journal-title":"Signal Transduct Target Ther"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1003884","article-title":"Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production","volume":"187","author":"Clayton","year":"2011","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/ncb2000","article-title":"Rab27a and Rab27b control different steps of the exosome secretion pathway","volume":"12","author":"Ostrowski","year":"2010","journal-title":"Nat Cell Biol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12354","article-title":"Human CD4+CD39+ regulatory T cells produce adenosine upon co-expression of surface CD73 or contact with CD73+ exosomes or CD73+ cells","volume":"177","author":"Schuler","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/srep20254","article-title":"Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets","volume":"6","author":"Muller","year":"2016","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","first-page":"e1261243","DOI":"10.1080\/2162402X.2016.1261243","article-title":"Human tumor-derived exosomes (TEX) regulate Treg functions via cell surface signaling rather than uptake mechanisms","volume":"6","author":"Muller","year":"2017","journal-title":"Oncoimmunology"},{"key":"B64","doi-asserted-by":"publisher","first-page":"e2416501","DOI":"10.1002\/advs.202416501","article-title":"Tumor-associated glycan exploits adenosine receptor 2A signaling to facilitate immune evasion","volume":"12","author":"Cheng","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13355","article-title":"The concise guide to PHARMACOLOGY 2015\/16: transporters","volume":"172","author":"Alexander","year":"2015","journal-title":"Br J Pharmacol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.febslet.2004.11.109","article-title":"ADA2 isoform of adenosine deaminase from pleural fluid","volume":"579","author":"Andreasyan","year":"2005","journal-title":"FEBS Lett"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-0340","article-title":"Targeting adenosine with adenosine deaminase 2 to inhibit growth of solid tumors","volume":"81","author":"Wang","year":"2021","journal-title":"Cancer Res"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2016.02.010","article-title":"The adenosine metabolite inosine is a functional agonist of the adenosine A2A receptor with a unique signaling bias","volume":"28","author":"Welihinda","year":"2016","journal-title":"Cell Signal"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.1989.256.4.c799","article-title":"Turnover of adenosine in plasma of human and dog blood","volume":"256","author":"Moser","year":"1989","journal-title":"Am J Physiol Cell Physiol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1177\/00912700022008991","article-title":"Pharmacokinetics and pharmacodynamics of peldesine (BCX-34), a purine nucleoside phosphorylase inhibitor, following single and multiple oral doses in healthy volunteers","volume":"40","author":"Viegas","year":"2000","journal-title":"J Clin Pharmacol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.01.002","article-title":"Inosine induces stemness features in CAR-T cells and enhances potency","volume":"42","author":"Klysz","year":"2024","journal-title":"Cancer Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-020-0219-4","article-title":"Inosine is an alternative carbon source for CD8+-T-cell function under glucose restriction","volume":"2","author":"Wang","year":"2020","journal-title":"Nat Metab"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/SCIENCE.ABC3421","article-title":"Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy","volume":"369","author":"Mager","year":"2020","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.121.000445","article-title":"International union of basic and clinical pharmacology. CXII: adenosine receptors: A further update","volume":"74","author":"Ijzerman","year":"2022","journal-title":"Pharmacol Rev"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1621423114","article-title":"Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket","volume":"114","author":"Sun","year":"2017","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1021\/acsptsci.5c00057","article-title":"Insights from clinical trials on A2A adenosine receptor antagonists for cancer treatment","volume":"8","author":"Deb","year":"2025","journal-title":"ACS Pharmacol Transl Sci"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e000417","DOI":"10.1136\/jitc-2019-000417","article-title":"Small molecule AZD4635 inhibitor of A2A R signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity","volume":"8","author":"Borodovsky","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B78","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.cell.2020.03.003","article-title":"Impact of GPCR structures on drug discovery","volume":"181","author":"Congreve","year":"2020","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0066-7","article-title":"Istradefylline: First global approval","volume":"73","author":"Dungo","year":"2013","journal-title":"Drugs"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.0c05741","article-title":"Design, synthesis, and biological activity studies of istradefylline derivatives based on adenine as A2A receptor antagonists","volume":"6","author":"Wang","year":"2021","journal-title":"ACS Omega"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2025.107039","article-title":"A2A receptor antagonist 4-(2-((6-Amino-9-ethyl-8-(furan-2-yl)-9H-purin-2-yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment","volume":"207","author":"Murugesan","year":"2025","journal-title":"Eur J Pharm Sci"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01691","article-title":"Discovery of the first efficacious adenosine 2A receptor negative allosteric modulators for high adenosine cancer immunotherapies","volume":"68","author":"Boujut","year":"2025","journal-title":"J Med Chem"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a011148","article-title":"The cyclic AMP pathway","volume":"4","author":"Sassone-Corsi","year":"2012","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2023.12.002","article-title":"Structural insights into membrane adenylyl cyclases, initiators of cAMP signaling","volume":"49","author":"Schuster","year":"2024","journal-title":"Trends Biochem Sci"},{"key":"B85","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1152\/physrev.00021.2020","article-title":"G protein-coupled receptor-G protein interactions: a single-molecule perspective","volume":"101","author":"Calebiro","year":"2021","journal-title":"Physiol Rev"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0236-6","article-title":"Structure of the adenosine-bound human adenosine A1 receptor-Gi complex","volume":"558","author":"Draper-Joyce","year":"2018","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.2174\/156800910791208535","article-title":"Targeting CREB for cancer therapy: friend or foe","volume":"10","author":"Xiao","year":"2010","journal-title":"Curr Cancer Drug Targets"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-020-03525-8","article-title":"What turns CREB on? And off? And why does it matter","volume":"77","author":"Steven","year":"2020","journal-title":"Cell Mol Life Sci"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2024.01.004","article-title":"cAMP signaling: a remarkably regional affair","volume":"49","author":"Bock","year":"2024","journal-title":"Trends Biochem Sci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s40164-020-00191-1","article-title":"Complex roles of cAMP\u2013PKA\u2013CREB signaling in cancer","volume":"9","author":"Zhang","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-019-02722-6","article-title":"CD73 expression and pathologic response to neoadjuvant chemotherapy in triple negative breast cancer","volume":"476","author":"Cerbelli","year":"2020","journal-title":"Virchows Archiv"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M113.455675","article-title":"Protein kinase a modulates transforming growth factor-\u03b2 signaling through a direct interaction with Smad4 protein","volume":"288","author":"Yang","year":"2013","journal-title":"J Biol Chem"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.07.036","article-title":"TGF-\u03b2 signaling in health and disease","volume":"186","author":"Massagu\u00e9","year":"2023","journal-title":"Cell"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-0631","article-title":"Wnt\/\u03b2-catenin and 3\u2032,5\u2032-cyclic adenosine 5\u2032-monophosphate\/protein kinase a signaling pathways alterations and somatic \u03b2-catenin gene mutations in the progression of adrenocortical tumors","volume":"93","author":"Gaujoux","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.E19-03-0136","article-title":"Adenosine interaction with adenosine receptor A2a promotes gastric cancer metastasis by enhancing PI3K-AKT-mTOR signaling","volume":"30","author":"Shi","year":"2019","journal-title":"Mol Biol Cell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13092105","article-title":"Increased extracellular adenosine in radiotherapy-resistant breast cancer cells enhances tumor progression through A2AR-Akt-\u03b2-catenin signaling","volume":"13","author":"Jin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B97","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ejca.2022.04.025","article-title":"The regulation of CD73 in non-small cell lung cancer","volume":"170","author":"Han","year":"2022","journal-title":"Eur J Cancer"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.02.012","article-title":"Exploiting the therapeutic implications of KRAS inhibition on tumor immunity","volume":"42","author":"Molina-Arcas","year":"2024","journal-title":"Cancer Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.02.049","article-title":"KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition","volume":"41","author":"Adderley","year":"2019","journal-title":"EBioMedicine"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3655","article-title":"Facts and hopes on RAS inhibitors and cancer immunotherapy","volume":"29","author":"Boumelha","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2025.177864","article-title":"Comparative analysis of the antiglioblastoma activity of adenosine A2A receptor and CK1\u03b4 blockers","volume":"1002","author":"Murugesan","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-022-09909-8","article-title":"Istradefylline modulates purinergic enzymes and reduces Malignancy-associated factors in B16F10 melanoma cells","volume":"19","author":"da Silva","year":"2023","journal-title":"Purinergic Signal"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-02-136325","article-title":"Adenosine receptors in regulation of dendritic cell differentiation and function","volume":"112","author":"Novitskiy","year":"2008","journal-title":"Blood"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e010126","DOI":"10.1136\/jitc-2024-010126","article-title":"Targeting adenosine enhances immunotherapy in MSS colorectal cancer with EGFRvIII mutation","volume":"13","author":"Sun","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2012.00190","article-title":"The development and immunosuppressive functions of CD4+ CD25+ FoxP3+ regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway","volume":"3","author":"Ohta","year":"2012","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1189\/jlb.0113043","article-title":"Adenosine augments IL-10-induced STAT3 signaling in M2c macrophages","volume":"94","author":"Koscs\u00f3","year":"2013","journal-title":"J Leukoc Biol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900765","article-title":"Adenosine receptor signaling targets both PKA and epac pathways to polarize dendritic cells to a suppressive phenotype","volume":"203","author":"Kayhan","year":"2019","journal-title":"J Immunol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e49416","DOI":"10.7554\/eLife.49416","article-title":"Inhibition of IRF4 in dendritic cells by PRR-independent and-dependent signals inhibit Th2 and promote Th17 responses","volume":"9","author":"Lee","year":"2020","journal-title":"Elife"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2011.12.019","article-title":"Stat3 and gfi-1 transcription factors control th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression","volume":"36","author":"Chalmin","year":"2012","journal-title":"Immunity"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1016\/s0021-9258(18)69210-5","article-title":"Locus of inhibitory action of cAMP-dependent protein kinase in the antigen receptor-triggered cytotoxic T lymphocyte activation pathway","volume":"263","author":"Takayama","year":"1988","journal-title":"J Biol Chem"},{"key":"B111","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1186\/s40425-019-0719-5","article-title":"Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8+ T cells","volume":"7","author":"Mastelic-Gavillet","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.159.11.5450","article-title":"Role of cyclic AMP response element-binding protein in cyclic AMP inhibition of NF-kappaB-mediated transcription","volume":"159","author":"Parry","year":"1997","journal-title":"J Immunol"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20070109","article-title":"CREB\/ATF-dependent T cell receptor-induced FoxP3 gene expression: A role for DNA methylation","volume":"204","author":"Kim","year":"2007","journal-title":"J Exp Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3565(24)29287-9","article-title":"Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-\u03baB and nuclear factor of activated T cells activation","volume":"299","author":"Jimenez","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1009463108","article-title":"Regulatory T cells facilitate the nuclear accumulation of inducible cAMP early repressor (ICER) and suppress nuclear factor of activated T cell c1 (NFATc1)","volume":"108","author":"Vaeth","year":"2011","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adk2693","article-title":"Plasticity and lineage commitment of individual TH1 cells are determined by stable T- bet expression quantities","volume":"10","author":"Hegazy","year":"2024","journal-title":"Sci Adv"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0909357106","article-title":"The transcription factors T-bet and GATA-3 control alternative pathways of T-cell differentiation through a shared set of target genes","volume":"106","author":"Jenner","year":"2009","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.09.011","article-title":"The cancer-immunity cycle: Indication, genotype, and immunotype","volume":"56","author":"Mellman","year":"2023","journal-title":"Immunity"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-061020-053702","article-title":"Cytokine regulation and function in T cells","volume":"39","author":"Dong","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-074948","article-title":"Natural killer cells: from innate to adaptive features","volume":"39","author":"Mujal","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24423","article-title":"Adenosine A2A receptor ligand recognition and signaling is blocked by A2B receptors","volume":"9","author":"Hinz","year":"2018","journal-title":"Oncotarget"},{"key":"B122","doi-asserted-by":"publisher","first-page":"e004592","DOI":"10.1136\/jitc-2022-004592","article-title":"A2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models","volume":"10","author":"Tay","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0833","article-title":"The expression of adenosine A2B receptor on antigen-presenting cells suppresses CD8+T-cell responses and promotes tumor growth","volume":"8","author":"Chen","year":"2020","journal-title":"Cancer Immunol Res"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0843","article-title":"Dual A2A\/A2B adenosine receptor antagonist M1069 counteracts immuno-suppressive mechanisms of adenosine and reduces tumor growth in vivo","volume":"23","author":"Schiemann","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-22-0194","article-title":"Bintrafusp alfa, an anti-PD-L1:TGF\u03b2 Trap fusion protein, in patients with ctDNA-positive, liver-limited metastatic colorectal cancer","volume":"2","author":"Morris","year":"2022","journal-title":"Cancer Res Commun"},{"key":"B126","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccell.2016.06.025","article-title":"Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses","volume":"30","author":"Young","year":"2016","journal-title":"Cancer Cell"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-011-1155-7","article-title":"Enhancement of tumor immunotherapy by deletion of the A 2A adenosine receptor","volume":"61","author":"Waickman","year":"2012","journal-title":"Cancer Immunol Immunother"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-22-0113","article-title":"Adenosine A2a receptor antagonism restores additive cytotoxicity by cytotoxic T cells in metabolically perturbed tumors","volume":"10","author":"Slaats","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"e004114","DOI":"10.1136\/jitc-2021-004114","article-title":"Genetic characteristics involving the PD-1\/PD-L1\/L2 and CD73\/A2aR axes and the immunosuppressive microenvironment in DLBCL","volume":"10","author":"Zhang","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.add6626","article-title":"Proteolytic regulation of CD73 by TRIM21 orchestrates tumor immunogenicity","volume":"9","author":"Fu","year":"2023","journal-title":"Sci Adv"},{"key":"B131","doi-asserted-by":"publisher","first-page":"e176390","DOI":"10.1172\/JCI176390","article-title":"Pharmacological suppression of the OTUD4\/CD73 proteolytic axis revives antitumor immunity against immune-suppressive breast cancers","volume":"134","author":"Zhu","year":"2024","journal-title":"J Clin Invest"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2012.09.007","article-title":"Controversies on the role of Th17 in cancer: A TGF-\u03b2-dependent immunosuppressive activity","volume":"18","author":"Martin","year":"2012","journal-title":"Trends Mol Med"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00276","article-title":"Th17 cells in cancer: The ultimate identity crisis","volume":"5","author":"Bailey","year":"2014","journal-title":"Front Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/ni1496","article-title":"Interleukins 1\u03b2 and 6 but not transforming growth factor-\u03b2 are essential for the differentiation of interleukin 17-producing human T helper cells","volume":"8","author":"Acosta-Rodriguez","year":"2007","journal-title":"Nat Immunol"},{"key":"B135","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1038\/s41467-020-16363-w","article-title":"TGF-\u03b2 signaling in Th17 cells promotes IL-22 production and colitis-associated colon cancer","volume":"11","author":"Perez","year":"2020","journal-title":"Nat Commun"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1610","article-title":"The differentiation of human TH-17 cells requires transforming growth factor-\u03b2 and induction of the nuclear receptor ROR\u03b3t","volume":"9","author":"Manel","year":"2008","journal-title":"Nat Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"e20240445","DOI":"10.1084\/jem.20240445","article-title":"Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39","volume":"222","author":"Tan","year":"2025","journal-title":"J Exp Med"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3868","article-title":"Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor","volume":"18","author":"Maj","year":"2017","journal-title":"Nat Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.7150\/jca.43966","article-title":"A2AR antagonism with DZD2269 augments antitumor efficacy of irradiation in murine model","volume":"11","author":"Huang","year":"2020","journal-title":"J Cancer"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.10.040192.003021","article-title":"Physiological and molecular mechanisms of lymphocyte homing","volume":"10","author":"Picker","year":"1992","journal-title":"Annu Rev Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2023.08.009","article-title":"Tertiary lymphoid structures and B cells: An intratumoral immunity cycle","volume":"56","author":"Fridman","year":"2023","journal-title":"Immunity"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-22-2589","article-title":"Spatial positioning of immune hotspots reflects the interplay between B and T cells in lung squamous cell carcinoma","volume":"83","author":"Zhang","year":"2023","journal-title":"Cancer Res"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1126\/science.adj4857","article-title":"A blueprint for tumor-infiltrating B cells across human cancers","volume":"384","author":"Ma","year":"2024","journal-title":"Science"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101220-015603","article-title":"B cell function in the tumor microenvironment","volume":"40","author":"Downs-Canner","year":"2022","journal-title":"Annu Rev Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1478506","article-title":"Hypoxia-adenosinergic regulation of B cell responses","volume":"15","author":"Pruitt","year":"2024","journal-title":"Front Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02535-6","article-title":"Adenosine-producing regulatory B cells in head and neck cancer","volume":"69","author":"Jeske","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"B147","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.immuni.2019.01.010","article-title":"Specific decrease in B-cell-derived extracellular vesicles enhances post-chemotherapeutic CD8 + T cell responses","volume":"50","author":"Zhang","year":"2019","journal-title":"Immunity"},{"key":"B148","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.immuni.2022.02.001","article-title":"Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer","volume":"55","author":"Meylan","year":"2022","journal-title":"Immunity"},{"key":"B149","doi-asserted-by":"publisher","first-page":"e006770","DOI":"10.1136\/jitc-2023-006770","article-title":"Location of CD39 + T cell subpopulations within tumors predict differential outcomes in non-small cell lung cancer","volume":"11","author":"Koppensteiner","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B150","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing cancer immunotherapies that engage T cells and NK cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-025-03375-x","article-title":"Natural killer cells: the immune frontline against circulating tumor cells","volume":"44","author":"Masmoudi","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.01.004","article-title":"NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control","volume":"172","author":"B\u00f6ttcher","year":"2018","journal-title":"Cell"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03260-y","article-title":"CAR \u03b3\u03b4 T cells for cancer immunotherapy. Is the field more yellow than green","volume":"72","author":"Ganapathy","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-1017","article-title":"Engineered CAR-NK Cells with Tolerance to H2O2 and Suppress Postoperative Relapse of Triple-Negative Breast Cancers","volume":"12","author":"Liu","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B155","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40425-018-0441-8","article-title":"Purinergic targeting enhances immunotherapy of CD73+ solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells","volume":"6","author":"Wang","year":"2018","journal-title":"J Immunother Cancer"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine receptor 2A blockade increases the efficacy of anti-PD-1 through enhanced antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1308209110","article-title":"Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors","volume":"110","author":"Beavis","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2826","article-title":"A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment","volume":"78","author":"Young","year":"2018","journal-title":"Cancer Res"},{"key":"B159","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41392-023-01653-8","article-title":"\u03b3\u03b4 T cells: origin and fate, subsets, diseases and immunotherapy","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B160","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41586-022-05593-1","article-title":"\u03b3\u03b4 T cells are effectors of immunotherapy in cancers with HLA class I defects","volume":"613","author":"de Vries","year":"2023","journal-title":"Nature"},{"key":"B161","doi-asserted-by":"publisher","first-page":"e1379642","DOI":"10.1080\/2162402X.2017.1379642","article-title":"IL-21 promotes the development of a CD73-positive V\u03b39V\u03b42 T cell regulatory population","volume":"7","author":"Barjon","year":"2017","journal-title":"Oncoimmunology"},{"key":"B162","doi-asserted-by":"publisher","first-page":"e108932","DOI":"10.1371\/journal.pone.0108932","article-title":"Roles of the adenosine receptor and CD73 in the regulatory effect of \u03b3\u03b4 T cells","volume":"9","author":"Liang","year":"2014","journal-title":"PloS One"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00014","article-title":"The emerging roles of gamma-delta T cells in tissue inflammation in experimental autoimmune encephalomyelitis","volume":"7","author":"Malik","year":"2016","journal-title":"Front Immunol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0900241","article-title":"Major role of \u03b3\u03b4 T cells in the generation of IL-17+ Uveitogenic T cells","volume":"183","author":"Cui","year":"2009","journal-title":"J Immunol"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1002\/JLB.3MA0420-278RR","article-title":"Identification of a regulatory V\u03b41 gamma delta T cell subpopulation expressing CD73 in human breast cancer","volume":"107","author":"Chabab","year":"2020","journal-title":"J Leukoc Biol"},{"key":"B166","doi-asserted-by":"publisher","first-page":"e1277305","DOI":"10.1080\/2162402X.2016.1277305","article-title":"Tumor-infiltrating CD39+ \u03b3\u03b4Tregs are novel immunosuppressive T cells in human colorectal cancer","volume":"6","author":"Hu","year":"2017","journal-title":"Oncoimmunology"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29125","article-title":"New insights into the regulation of inflammation by adenosine","volume":"116","author":"Linden","year":"2006","journal-title":"J Clin Invest"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1096\/fj.11-190934","article-title":"Adenosine promotes alternative macrophage activation via A2Aand A2B receptors","volume":"26","author":"Cs\u00f3ka","year":"2012","journal-title":"FASEB J"},{"key":"B169","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1146\/annurev-immunol-020711-074950","article-title":"The dendritic cell lineage: ontogeny and function of dendritic cells and their subsets in the steady state and the inflamed setting","volume":"31","author":"Merad","year":"2013","journal-title":"Annu Rev Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3583","article-title":"Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment","volume":"74","author":"Cekic","year":"2014","journal-title":"Cancer Res"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1080\/20013078.2017.1368823","article-title":"Dominant immunosuppression of dendritic cell function by prostate-cancer-derived exosomes","volume":"6","author":"Salimu","year":"2017","journal-title":"J Extracell Vesicles"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2020.04.019","article-title":"Charting the roadmap of T cell exhaustion","volume":"52","author":"Chu","year":"2020","journal-title":"Immunity"},{"key":"B175","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental relationships of four exhausted CD8+ T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-547349","article-title":"Lowest numbers of primary CD8+ T cells can reconstitute protective immunity upon adoptive immunotherapy","volume":"124","author":"Stemberger","year":"2014","journal-title":"Blood"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-06-578989","article-title":"Big bang theory of stem-like T cells confirmed","volume":"124","author":"Restifo","year":"2014","journal-title":"Blood"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion.\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1548234","article-title":"Deciphering T-cell exhaustion in the tumor microenvironment: paving the way for innovative solid tumor therapies","volume":"16","author":"Nair","year":"2025","journal-title":"Front Immunol"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2021.03.001","article-title":"Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells","volume":"21","author":"Newton","year":"2021","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3581","article-title":"Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment","volume":"74","author":"Cekic","year":"2014","journal-title":"Cancer Res"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1096\/fj.10-155192","article-title":"Adenosine A 2A receptor activation protects CD4 + T lymphocytes against activation-induced cell death","volume":"24","author":"Himer","year":"2010","journal-title":"FASEB J"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb9847","article-title":"Stem-like CD8 T cells mediate response of adoptive cell immunotherapy against human cancer","volume":"370","author":"Krishna","year":"2020","journal-title":"Science"},{"key":"B184","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.immuni.2022.12.001","article-title":"The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer","volume":"56","author":"Chow","year":"2023","journal-title":"Immunity"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2684","article-title":"CD39 expression defines cell exhaustion in tumor-infiltrating CD8+ T cells","volume":"78","author":"Canale","year":"2018","journal-title":"Cancer Res"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2024.2346359","article-title":"Expression of CD39 is associated with T cell exhaustion in ovarian cancer and its blockade reverts T cell dysfunction","volume":"13","author":"Witt","year":"2024","journal-title":"Oncoimmunology"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02345-0","article-title":"Intratumoral dendritic cell\u2013CD4+ T helper cell niches enable CD8+ T cell differentiation following PD-1 blockade in hepatocellular carcinoma","volume":"29","author":"Magen","year":"2023","journal-title":"Nat Med"},{"key":"B188","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.1016\/j.celrep.2019.04.091","article-title":"Blocking antibodies targeting the CD39\/CD73 immunosuppressive pathway unleash immune responses in combination cancer therapies","volume":"27","author":"Perrot","year":"2019","journal-title":"Cell Rep"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.31534","article-title":"Specific blockade CD73 alters the \u201cexhausted\u201d phenotype of T cells in head and neck squamous cell carcinoma","volume":"143","author":"Deng","year":"2018","journal-title":"Int J Cancer"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1930391","article-title":"Increased frequency of TIGIT+CD73-CD8+ T cells with a TOX+ TCF-1low profile in patients with newly diagnosed and relapsed AML","volume":"10","author":"Brauneck","year":"2021","journal-title":"Oncoimmunology"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1744946","article-title":"Enhanced expression of CD39 and CD73 on T cells in the regulation of anti-tumor immune responses","volume":"9","author":"Shevchenko","year":"2020","journal-title":"Oncoimmunology"},{"key":"B192","doi-asserted-by":"publisher","first-page":"e002755","DOI":"10.1136\/jitc-2021-002755","article-title":"Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy","volume":"9","author":"He","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.03.014","article-title":"Secretion of bispecific protein of anti-PD-1 fused with TGF-\u03b2 trap enhances antitumor efficacy of CAR-T cell therapy","volume":"21","author":"Chen","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2016.08.011","article-title":"LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells","volume":"24","author":"Brand","year":"2016","journal-title":"Cell Metab"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-17-2405","article-title":"Autocrine adenosine regulates tumor polyfunctional CD73+CD4+ Effector T cells devoid of immune checkpoints","volume":"78","author":"Gourdin","year":"2018","journal-title":"Cancer Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01529-7","article-title":"The GPCR\u2013G\u03b1s\u2013PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure","volume":"24","author":"Wu","year":"2023","journal-title":"Nat Immunol"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1201632","article-title":"The immune checkpoint adenosine 2A receptor is associated with aggressive clinical outcomes and reflects an immunosuppressive tumor microenvironment in human breast cancer","volume":"14","author":"Zohair","year":"2023","journal-title":"Front Immunol"},{"key":"B198","doi-asserted-by":"publisher","first-page":"e134386","DOI":"10.1172\/jci.insight.134386","article-title":"Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration","volume":"5","author":"Ott","year":"2020","journal-title":"JCI Insight"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02972-8","article-title":"Adenosine 2A receptor and TIM3 suppress cytolytic killing of tumor cells via cytoskeletal polarization","volume":"5","author":"Edmunds","year":"2022","journal-title":"Commun Biol"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-017-0543-6","article-title":"CRISPR-Cas9 mediated LAG-3 disruption in CAR-T cells","volume":"11","author":"Zhang","year":"2017","journal-title":"Front Med"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"New Engl J Med"},{"key":"B202","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","article-title":"Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models","volume":"67","author":"Leone","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"B203","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-025-01666-6","article-title":"Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib\/II trial","volume":"18","author":"Chen","year":"2025","journal-title":"J Hematol Oncol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1158\/2159-8290.CD-19-0980","article-title":"Adenosine 2A receptor blockade as an immunotherapy for treatment-refractory renal cell cancer","volume":"10","author":"Fong","year":"2020","journal-title":"Cancer Discov"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0617-487","article-title":"Industry \u201croad tests\u201d new wave of immune checkpoints","volume":"35","author":"Garber","year":"2017","journal-title":"Nat Biotechnol"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-1280","article-title":"Lessons from the A2A adenosine receptor antagonist\u2013 enabled tumor regression and survival in patients with treatment-refractory renal cell cancer","volume":"10","author":"Sitkovsky","year":"2020","journal-title":"Cancer Discov"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2183","article-title":"Adenosine signaling is prognostic for cancer outcome and has predictive utility for immunotherapeutic response","volume":"26","author":"Sidders","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B208","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1016\/j.ccell.2022.05.004","article-title":"Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer","volume":"40","author":"Kersten","year":"2022","journal-title":"Cancer Cell"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08290-3","article-title":"Evolution of myeloid-mediated immunotherapy resistance in prostate cancer","volume":"637","author":"Lyu","year":"2025","journal-title":"Nature"},{"key":"B210","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-017-0013-8","article-title":"Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma","volume":"2","author":"Reuben","year":"2017","journal-title":"NPJ Genom Med"},{"key":"B212","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40164-022-00277-y","article-title":"Heterogeneity of the tumor immune microenvironment and its clinical relevance","volume":"11","author":"Jia","year":"2022","journal-title":"Exp Hematol Oncol"},{"key":"B213","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1038\/s41467-024-45723-z","article-title":"Tumor histoculture captures the dynamic interactions between tumor and immune components in response to anti-PD1 in head and neck cancer","volume":"15","author":"Basak","year":"2024","journal-title":"Nat Commun"},{"key":"B214","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.immuni.2018.06.006","article-title":"Tumor cell-intrinsic factors underlie heterogeneity of immune cell infiltration and response to immunotherapy","volume":"49","author":"Li","year":"2018","journal-title":"Immunity"},{"key":"B215","doi-asserted-by":"publisher","first-page":"e004440","DOI":"10.1136\/jitc-2021-004440","article-title":"Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer","volume":"10","author":"Lopez De Rodas","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.12.009","article-title":"Neoadjuvant radioimmunotherapy synergy in triple-negative breast cancer: Is microenvironment-guided patient selection on the horizon","volume":"42","author":"Shaitelman","year":"2024","journal-title":"Cancer Cell"},{"key":"B217","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/j.cell.2018.07.009","article-title":"Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids","volume":"174","author":"Dijkstra","year":"2018","journal-title":"Cell"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01398-3","article-title":"An ex vivo tumor fragment platform to dissect response to PD-1 blockade in cancer","volume":"27","author":"Voabil","year":"2021","journal-title":"Nat Med"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1414376","article-title":"Mismatch repair-proficient tumor footprints in the sands of immune desert: mechanistic constraints and precision platforms","volume":"15","author":"Majumder","year":"2024","journal-title":"Front Immunol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216182","article-title":"Immune-checkpoint inhibitor resistance in cancer treatment: Current progress and future directions","volume":"562","author":"Zhang","year":"2023","journal-title":"Cancer Lett"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.7150\/thno.108931","article-title":"Nanomaterials-mediated adenosine pathway inhibition for strengthening cancer immunotherapy","volume":"15","author":"Zhu","year":"2025","journal-title":"Theranostics"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241713274","article-title":"Hepatocellular carcinoma: past and present challenges and progress in molecular classification and precision oncology","volume":"24","author":"Coffin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32740","article-title":"The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma","volume":"77","author":"Donne","year":"2023","journal-title":"Hepatology"},{"key":"B224","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1186\/s13046-025-03416-5","article-title":"Research progress of CD73-adenosine signaling regulating hepatocellular carcinoma through tumor microenvironment","volume":"44","author":"Shan","year":"2025","journal-title":"J Exp Clin Cancer Res"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1007\/s13105-024-01061-8","article-title":"Prognostic model development using novel genetic signature associated with adenosine metabolism and immune status for patients with hepatocellular carcinoma","volume":"81","author":"Chen","year":"2025","journal-title":"J Physiol Biochem"},{"key":"B226","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s12943-023-01733-x","article-title":"CD39\/CD73\/A2AR pathway and cancer immunotherapy","volume":"22","author":"Xia","year":"2023","journal-title":"Mol Cancer"},{"key":"B227","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13045-019-0724-7","article-title":"CD73 promotes hepatocellular carcinoma progression and metastasis via activating PI3K\/AKT signaling by inducing Rap1-mediated membrane localization of P110\u03b2 and predicts poor prognosis","volume":"12","author":"Ma","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-020-0845-z","article-title":"CD73 sustained cancer-stem-cell traits by promoting SOX9 expression and stability in hepatocellular carcinoma","volume":"13","author":"Ma","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101188","article-title":"Adenosine A2A receptor is a tumor suppressor of NASH-associated hepatocellular carcinoma","volume":"4","author":"Allard","year":"2023","journal-title":"Cell Rep Med"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.1068","article-title":"Deciphering adenosine signaling in hepatocellular carcinoma: Pathways, prognostic models, and therapeutic implication","volume":"31","author":"Yang","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B231","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41467-017-00530-7","article-title":"Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2\/CD39L1 in hepatocellular carcinoma","volume":"8","author":"Chiu","year":"2017","journal-title":"Nat Commun"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100959","article-title":"Adenosine A2a receptor inhibition increases the anti-tumor efficacy of anti-PD1 treatment in murine hepatobiliary cancers","volume":"6","author":"Myojin","year":"2023","journal-title":"JHEP Rep"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106853","article-title":"Adenosine and adenosine receptors in colorectal cancer","volume":"87","author":"Hajizadeh","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-011-9228-9","article-title":"Impact of CD39 and purinergic signalling on the growth and metastasis of colorectal cancer","volume":"7","author":"K\u00fcnzli","year":"2011","journal-title":"Purinergic Signal"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000094","article-title":"Recent advancement in understanding colitis-associated tumorigenesis","volume":"20","author":"Low","year":"2014","journal-title":"Inflammation Bowel Dis"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1002\/jso.23056","article-title":"High expression of CD73 as a poor prognostic biomarker in human colorectal cancer","volume":"106","author":"Wu","year":"2012","journal-title":"J Surg Oncol"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1007\/s00345-022-04165-2","article-title":"The association between prostatitis and risk of prostate cancer: a National Health Insurance Database study","volume":"40","author":"Jung","year":"2022","journal-title":"World J Urol"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.184","article-title":"Synergistic interaction of benign prostatic hyperplasia and prostatitis on prostate cancer risk","volume":"108","author":"Hung","year":"2013","journal-title":"Br J Cancer"},{"key":"B239","doi-asserted-by":"publisher","first-page":"e004089","DOI":"10.1136\/jitc-2021-004089","article-title":"Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy","volume":"10","author":"Augustin","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01056-8","article-title":"Next generation of immune checkpoint inhibitors and beyond","volume":"14","author":"Marin-Acevedo","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.965429","article-title":"Association of adenosine signaling gene signature with estrogen receptor-positive breast and prostate cancer bone metastasis","volume":"9","author":"Shropshire","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.402","article-title":"Tumour-derived alkaline phosphatase regulates tumour growth, epithelial plasticity and disease-free survival in metastatic prostate cancer","volume":"116","author":"Rao","year":"2017","journal-title":"Br J Cancer"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.86","article-title":"Targeting immunosuppressive adenosine in cancer","volume":"17","author":"Vijayan","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1181","article-title":"CD73 expression is an independent prognostic factor in prostate cancer","volume":"22","author":"Leclerc","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B245","doi-asserted-by":"publisher","first-page":"e473636","DOI":"10.1200\/EDBK-25-473636","article-title":"State of the art: personalizing treatment for patients with metastatic castration-resistant prostate cancer","volume":"45","author":"Abida","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B246","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the checkMate 650 trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"key":"B247","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1200\/JCO.19.01638","article-title":"Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: Multicohort, open-label phase II KEYNOTE-199 study","volume":"38","author":"Antonarakis","year":"2020","journal-title":"J Clin Oncol"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-0612","article-title":"Phase ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors","volume":"28","author":"Lim","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B249","doi-asserted-by":"publisher","first-page":"e473616","DOI":"10.1200\/EDBK-25-473616","article-title":"Capturing unicorns: targeting cancers with TP53 mutations, RAS alterations beyond G12C, and MTAP loss-no target is out of the realm of possibility","volume":"45","author":"Shah","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2014.04.017","article-title":"MTAP is an independent prognosis marker and the concordant loss of MTAP and p16 expression predicts short survival in non-small cell lung cancer patients","volume":"40","author":"Su","year":"2014","journal-title":"Eur J Surg Oncol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1016\/j.euo.2021.10.006","article-title":"Integrative clinical and genomic characterization of MTAP-deficient metastatic urothelial cancer","volume":"6","author":"Alhalabi","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"B252","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oncolo\/oyae011","article-title":"Methylthioadenosine phosphorylase genomic loss in advanced gastrointestinal cancers","volume":"29","author":"Ngoi","year":"2024","journal-title":"Oncologist"},{"key":"B253","doi-asserted-by":"publisher","first-page":"4183","DOI":"10.1038\/s41598-022-07697-0","article-title":"MTAP loss correlates with an immunosuppressive profile in GBM and its substrate MTA stimulates alternative macrophage polarization","volume":"12","author":"Hansen","year":"2022","journal-title":"Sci Rep"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5214","article-title":"MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells","volume":"351","author":"Kryukov","year":"2016","journal-title":"Science"},{"key":"B255","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41467-022-29397-z","article-title":"MTAP deficiency creates an exploitable target for antifolate therapy in 9p21-loss cancers","volume":"13","author":"Alhalabi","year":"2022","journal-title":"Nat Commun"},{"key":"B256","doi-asserted-by":"publisher","first-page":"e009600","DOI":"10.1136\/jitc-2024-009600","article-title":"MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors","volume":"12","author":"Chen","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B257","doi-asserted-by":"publisher","first-page":"e104210","DOI":"10.1371\/journal.pone.0104210","article-title":"Methylthioadenosine reprograms macrophage activation through adenosine receptor stimulation","volume":"9","author":"Keyel","year":"2014","journal-title":"PloS One"},{"key":"B258","doi-asserted-by":"publisher","first-page":"e1184802","DOI":"10.1080\/2162402X.2016.1184802","article-title":"Suppressive effects of tumor cell-derived 5\u2032-deoxy-5\u2032-methylthioadenosine on human T cells","volume":"5","author":"Henrich","year":"2016","journal-title":"Oncoimmunology"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.09.005","article-title":"Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance","volume":"41","author":"Gjuka","year":"2023","journal-title":"Cancer Cell"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02128","article-title":"The oncometabolite 5\u2032-deoxy-5\u2032-methylthioadenosine blocks multiple signaling pathways of NK cell activation","volume":"11","author":"Jacobs","year":"2020","journal-title":"Front Immunol"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.3390\/cells13242114","article-title":"The tumor metabolite 5\u2019-deoxy-5\u2019Methylthioadenosine (MTA) inhibits maturation and T cell-stimulating capacity of dendritic cells","volume":"13","author":"Brummer","year":"2024","journal-title":"Cells Cells"},{"key":"B262","doi-asserted-by":"publisher","first-page":"5606","DOI":"10.1038\/s41467-021-25894-9","article-title":"9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy","volume":"12","author":"Han","year":"2021","journal-title":"Nat Commun"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(01)00269-0","article-title":"Arginine methylation of STAT1 modulates IFN\u03b1\/\u03b2-induced transcription","volume":"104","author":"Mowen","year":"2001","journal-title":"Cell"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1172\/JCI112050","article-title":"Identification of a point mutation in the adenosine deaminase gene responsible for immunodeficiency","volume":"76","author":"Bonthron","year":"1985","journal-title":"J Clin Invest"},{"key":"B265","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-017-0433-3","article-title":"Adenosine deaminase (ADA)-deficient severe combined immune deficiency (SCID): molecular pathogenesis and clinical manifestations","volume":"37","author":"Bradford","year":"2017","journal-title":"J Clin Immunol"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1\/PD-l1 blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov"},{"key":"B267","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1186\/s12967-024-05768-6","article-title":"CD38 as theranostic target in oncology","volume":"22","author":"Bocuzzi","year":"2024","journal-title":"J Transl Med"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.02.022","article-title":"CD38 as a novel immunosuppressive target in prostate cancer","volume":"79","author":"Oh","year":"2021","journal-title":"Eur Urol"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00760","article-title":"CD38 in adenosinergic pathways and metabolic re-programming in human multiple myeloma cells: In-tandem insights from basic science to therapy","volume":"10","author":"Horenstein","year":"2019","journal-title":"Front Immunol"},{"key":"B271","doi-asserted-by":"publisher","first-page":"e000987","DOI":"10.1136\/jitc-2020-000987","article-title":"Immunohistochemical scoring of CD38 in the tumor microenvironment predicts responsiveness to anti-PD-1\/PD-L1 immunotherapy in hepatocellular carcinoma","volume":"8","author":"Ng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B272","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00018-024-05539-y","article-title":"ENPP1\/CD203a-targeting heavy-chain antibody reveals cell-specific expression on human immune cells","volume":"82","author":"Lorenz","year":"2024","journal-title":"Cell Mol Life Sci"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0932","article-title":"Tumor ENPP1 (CD203a)\/haptoglobin axis exploits myeloid-derived suppressor cells to promote post-radiotherapy local recurrence in breast cancer","volume":"12","author":"Ruiz-Fern\u00e1ndez de C\u00f3rdoba","year":"2022","journal-title":"Cancer Discov"},{"key":"B274","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.1038\/s41467-018-06922-7","article-title":"Structural insights into cGAMP degradation by Ecto-nucleotide pyrophosphatase phosphodiesterase 1","volume":"9","author":"Kato","year":"2018","journal-title":"Nat Commun"},{"key":"B275","doi-asserted-by":"publisher","first-page":"e2308131","DOI":"10.1002\/advs.202308131","article-title":"Tumor Exosomal ENPP1 Hydrolyzes cGAMP to Inhibit cGAS-STING Signaling","volume":"11","author":"An","year":"2024","journal-title":"Advanced Sci"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2025.102336","article-title":"ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B277","doi-asserted-by":"publisher","first-page":"4793","DOI":"10.1038\/s41467-025-59874-0","article-title":"Oral ENPP1 inhibitor designed using generative AI as next generation STING modulator for solid tumors","volume":"16","author":"Pu","year":"2025","journal-title":"Nat Commun"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.TARGETEDTHERAP-P021","article-title":"Abstract P021: Countering adenosine (ADO) in rectal cancer to improve RT responses to immune checkpoint blockade: a trial to test the safety and efficacy of PD1 (AB122) and ADO dual receptor (AB928) antagonists with chemotherapy after short-course RT","volume":"31","author":"Golden","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B279","doi-asserted-by":"publisher","first-page":"e003013","DOI":"10.1136\/jitc-2021-003013","article-title":"Immunosuppressive metabolites in tumoral immune evasion: Redundancies, clinical efforts, and pathways forward","volume":"9","author":"Jennings","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B280","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun Signal"},{"key":"B281","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1186\/s13046-022-02511-1","article-title":"Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist","volume":"41","author":"Bai","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.ads6295","article-title":"Functional differences between rodent and human PD-1 linked to evolutionary divergence","volume":"10","author":"Masubuchi","year":"2025","journal-title":"Sci Immunol"},{"key":"B283","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/s43018-022-00346-5","article-title":"Cancer models for reverse and forward translation","volume":"3","year":"2022","journal-title":"Nat Cancer"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1222738110","article-title":"Conservation and divergence in the transcriptional programs of the human and mouse immune systems","volume":"110","author":"Shay","year":"2013","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.5981","article-title":"Final overall survival and molecular analysis in IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab vs sunitinib in patients with previously untreated metastatic renal cell carcinoma","volume":"8","author":"Motzer","year":"2022","journal-title":"JAMA Oncol"},{"key":"B286","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2618","article-title":"A phase I dose-escalation study of the HIF-2 alpha inhibitor DFF332 in patients with advanced clear-cell renal cell carcinoma","volume":"31","author":"Pal","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e14681","article-title":"ADPORT-601: First-in-human study of adenosine 2A (A2A) and adenosine 2B (A2B) receptor antagonists in patients with select advanced solid tumors","volume":"42","author":"Fong","year":"2024","journal-title":"J Clin Oncol"},{"key":"B288","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-SITC2024.0052","article-title":"52 The adenosine receptor antagonist etrumadenant reduces tumor adenosine-regulated NR4A gene expression and increases mCRC inflammation in patients from the ARC-9 trial","volume":"12","author":"Kim","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2742","article-title":"Phase i Study of Taminadenant (PBF509\/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer","volume":"28","author":"Chiappori","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.5518","article-title":"open-label, multicenter study to assess the safety, pharmacokinetics, and preliminary antitumor activity of AZD4635 both as monotherapy and in combination in patients with advanced solid Malignancies: Results from prostate cancer patients (NCT02740985)","volume":"38","author":"Lim","year":"2020","journal-title":"J Clin Oncol"},{"key":"B291","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2019.37.15_suppl.2505","article-title":"Immunobiology, preliminary safety, and efficacy of CPI-006, an anti-CD73 antibody with immune modulating activity, in a phase 1 trial in advanced cancers","volume":"37","author":"Luke","year":"2019","journal-title":"J Clin Oncol"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.5039","article-title":"ARC-6: A phase 1b\/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC)","volume":"39","author":"Subudhi","year":"2021","journal-title":"J Clin Oncol"},{"key":"B293","doi-asserted-by":"publisher","first-page":"e009063","DOI":"10.1136\/jitc-2024-009063","article-title":"Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic vision","volume":"12","author":"Emens","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B294","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03398-5","article-title":"Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data","volume":"31","author":"Yoo","year":"2025","journal-title":"Nat Med"},{"key":"B295","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat Commun"},{"key":"B296","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1402039","article-title":"Adenosine modulates NR4A orphan nuclear receptors to attenuate hyperinflammatory responses in monocytic cells","volume":"195","author":"Crean","year":"2015","journal-title":"J Immunol"},{"key":"B297","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1016\/j.cell.2024.04.023","article-title":"Osr2 functions as a biomechanical checkpoint to aggravate CD8+ T cell exhaustion in tumor","volume":"187","author":"Zhang","year":"2024","journal-title":"Cell"},{"key":"B298","doi-asserted-by":"publisher","DOI":"10.15252\/embj.201490786","article-title":"Molecular profiling of CD8 T cells from autochthonous melanoma identifies Maf as driver of T cell exhaustion","volume":"34","author":"Giordano","year":"2015","journal-title":"EMBO J."},{"key":"B299","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00507-y","article-title":"Intratumoural administration and tumour tissue targeting of cancer immunotherapies","volume":"18","author":"Melero","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"B300","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/j.chembiol.2021.10.012","article-title":"Systemic delivery of a targeted synthetic immunostimulant transforms the immune landscape for effective tumor regression","volume":"29","author":"Miller","year":"2022","journal-title":"Cell Chem Biol"},{"key":"B301","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1038\/s41467-021-24902-2","article-title":"Synergistic effect of tumor chemo-immunotherapy induced by leukocyte-hitchhiking thermal-sensitive micelles","volume":"12","author":"Qi","year":"2021","journal-title":"Nat Commun"},{"key":"B302","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat Med"},{"key":"B303","doi-asserted-by":"publisher","first-page":"e006842","DOI":"10.1136\/jitc-2023-006842","article-title":"CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models","volume":"11","author":"Ye","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B304","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1186\/s13046-022-02430-1","article-title":"Targeting purinergic pathway to enhance radiotherapy-induced immunogenic cancer cell death","volume":"41","author":"Bao","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B305","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh1261","article-title":"Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression","volume":"14","author":"Mao","year":"2022","journal-title":"Sci Transl Med"},{"key":"B306","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2025.123216","article-title":"Immunity\/metabolism dual-regulation via an acidity-triggered bioorthogonal assembly nanoplatform enhances glioblastoma immunotherapy by targeting CXCL12\/CXCR4 and adenosine-A2AR pathways","volume":"319","author":"Wei","year":"2025","journal-title":"Biomaterials"},{"key":"B307","doi-asserted-by":"publisher","first-page":"e2207200","DOI":"10.1002\/advs.202207200","article-title":"Dual-cascade activatable nanopotentiators reshaping adenosine metabolism for sono-chemodynamic-immunotherapy of deep tumors","volume":"10","author":"Zhan","year":"2023","journal-title":"Adv Sci"},{"key":"B308","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"key":"B309","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.tibtech.2014.10.006","article-title":"Synthetic immunology: Modulating the human immune system","volume":"33","author":"Geering","year":"2015","journal-title":"Trends Biotechnol"},{"key":"B310","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"key":"B311","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1362904","article-title":"Simultaneous targeting of Tim3 and A2a receptors modulates MSLN-CAR T cell antitumor function in a human cervical tumor xenograft model","volume":"15","author":"Soltantoyeh","year":"2024","journal-title":"Front Immunol"},{"key":"B312","doi-asserted-by":"publisher","first-page":"e20231106","DOI":"10.1084\/jem.20231106","article-title":"Hypoxia is linked to acquired resistance to immune checkpoint inhibitors in lung cancer","volume":"222","author":"Robles-Ote\u00edza","year":"2025","journal-title":"J Exp Med"},{"key":"B313","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-17-0502","article-title":"CAR-T cells surface-engineered with drug-encapsulated nanoparticles can ameliorate intratumoral T-cell hypofunction","volume":"6","author":"Siriwon","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B314","doi-asserted-by":"publisher","first-page":"4981","DOI":"10.1038\/s41467-022-32521-8","article-title":"Lactate increases stemness of CD8 + T cells to augment anti-tumor immunity","volume":"13","author":"Feng","year":"2022","journal-title":"Nat Commun"},{"key":"B315","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00860-8","article-title":"Claudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician\u2019s choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial","volume":"405","author":"Qi","year":"2025","journal-title":"Lancet"},{"key":"B316","doi-asserted-by":"publisher","DOI":"10.3389\/fmmed.2022.1026474","article-title":"Safety switch optimization enhances antibody-mediated elimination of CAR T cells","volume":"2","author":"Shabaneh","year":"2022","journal-title":"Front Mol Med"},{"key":"B317","doi-asserted-by":"publisher","DOI":"10.1056\/nejmra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"New Engl J Med"},{"key":"B318","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B319","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1509","article-title":"Tumor-host cometabolism collaborates to shape cancer immunity","volume":"14","author":"Wu","year":"2024","journal-title":"Cancer Discov"},{"key":"B320","doi-asserted-by":"publisher","DOI":"10.1016\/j.cels.2024.11.010","article-title":"Metabolic immunoengineering approaches to enhance CD8+ T cell-based cancer immunotherapy","volume":"15","author":"Feng","year":"2024","journal-title":"Cell Syst"},{"key":"B321","doi-asserted-by":"publisher","first-page":"e84280","DOI":"10.7554\/eLife.84280","article-title":"Oxygen levels at the time of activation determine T cell persistence and immunotherapeutic efficacy","volume":"12","author":"Cunha","year":"2023","journal-title":"Elife"},{"key":"B322","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2201445","article-title":"PD-1 blockade in mismatch repair\u2013deficient, locally advanced rectal cancer","volume":"386","author":"Cercek","year":"2022","journal-title":"New Engl J Med"},{"key":"B323","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands intratumoral memory T cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B324","doi-asserted-by":"publisher","first-page":"e2418985122","DOI":"10.1073\/pnas.2418985122","article-title":"Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1","volume":"122","author":"Mok","year":"2025","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B325","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0084","article-title":"Scalable manufacturing of CAR T cells for cancer immunotherapy","volume":"2","author":"Abou-El-Enein","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B326","doi-asserted-by":"publisher","first-page":"e0278950","DOI":"10.1371\/journal.pone.0278950","article-title":"Costs, effectiveness, and safety associated with Chimeric Antigen Receptor (CAR) T-cell therapy: Results from a comprehensive cancer center","volume":"17","author":"Chacim","year":"2022","journal-title":"PloS One"},{"key":"B327","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B328","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08508-4","article-title":"RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer","volume":"639","author":"Sethna","year":"2025","journal-title":"Nature"},{"key":"B329","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03283-5","article-title":"A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study","volume":"72","author":"Espa\u00f1ol-Rego","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B330","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B331","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"B332","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.08.003","article-title":"Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer","volume":"40","author":"Awad","year":"2022","journal-title":"Cancer Cell"},{"key":"B333","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2024.12.004","article-title":"Boosting CAR-T cell therapy through vaccine synergy","volume":"46","author":"Li","year":"2025","journal-title":"Trends Pharmacol Sci"},{"key":"B334","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100399","article-title":"Effector T cell responses unleashed by regulatory T cell ablation exacerbate oral squamous cell carcinoma","volume":"2","author":"Chao","year":"2021","journal-title":"Cell Rep Med"},{"key":"B335","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-03-081646","article-title":"A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells","volume":"111","author":"Zarek","year":"2008","journal-title":"Blood"},{"key":"B336","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02760-3","article-title":"Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial","volume":"30","author":"Pant","year":"2024","journal-title":"Nat Med"},{"key":"B337","doi-asserted-by":"publisher","first-page":"e2101222","DOI":"10.1002\/adhm.202101222","article-title":"A redox-responsive nanovaccine combined with A2A receptor antagonist for cancer immunotherapy","volume":"10","author":"Yan","year":"2021","journal-title":"Adv Healthc Mater"},{"key":"B338","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.C116.764043","article-title":"The GS protein-coupled A2a adenosine receptor controls T cell help in the germinal center","volume":"292","author":"Abbott","year":"2017","journal-title":"J Biol Chem"},{"key":"B339","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1601686","article-title":"Adenosine A2a receptor signals inhibit germinal center T follicular helper cell differentiation during the primary response to vaccination","volume":"198","author":"Schmiel","year":"2017","journal-title":"J Immunol"},{"key":"B340","doi-asserted-by":"publisher","DOI":"10.1177\/1010428317695021","article-title":"Increased efficacy of a dendritic cell\u2013based therapeutic cancer vaccine with adenosine receptor antagonist and CD73 inhibitor","volume":"39","author":"Arab","year":"2017","journal-title":"Tumor Biol"},{"key":"B341","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jconrel.2016.12.012","article-title":"CD73 specific siRNA loaded chitosan lactate nanoparticles potentiate the antitumor effect of a dendritic cell vaccine in 4T1 breast cancer bearing mice","volume":"246","author":"Jadidi-Niaragh","year":"2017","journal-title":"J Controlled Release"},{"key":"B342","doi-asserted-by":"publisher","first-page":"102240","DOI":"10.1016\/j.nano.2020.102240","article-title":"Silencing adenosine A2a receptor enhances dendritic cell-based cancer immunotherapy","volume":"29","author":"Masjedi","year":"2020","journal-title":"Nanomedicine"},{"key":"B343","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-024-02021-6","article-title":"PD-1 and CD73 on naive CD4+ T cells synergistically limit responses to self","volume":"26","author":"Nettersheim","year":"2025","journal-title":"Nat Immunol"},{"key":"B344","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.053","article-title":"The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution","volume":"181","author":"Rozenblatt-Rosen","year":"2020","journal-title":"Cell"},{"key":"B345","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-101097","article-title":"Differential expression of 5\u2032-UTR splice variants of the adenosine A 2A receptor gene in human granulocytes: identification, characterization, and functional impact on activation","volume":"22","author":"Kreth","year":"2008","journal-title":"FASEB J"},{"key":"B346","doi-asserted-by":"publisher","first-page":"e50279","DOI":"10.7554\/eLife.50279","article-title":"Common activation mechanism of class a GPCRs","volume":"8","author":"Zhou","year":"2019","journal-title":"Elife"},{"key":"B347","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1038\/s42003-023-05603-6","article-title":"Single-molecule visualization of human A2A adenosine receptor activation by a G protein and constitutively activating mutations","volume":"6","author":"Wei","year":"2023","journal-title":"Commun Biol"},{"key":"B348","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1124\/jpet.115.230003","article-title":"Ligand-independent adenosine A2B receptor constitutive activity as a promoter of prostate cancer cell proliferation","volume":"357","author":"Vecchio","year":"2016","journal-title":"J Pharmacol Exp Ther"},{"key":"B349","doi-asserted-by":"publisher","DOI":"10.1007\/s11302-011-9251-x","article-title":"Three \u201chotspots\u201d important for adenosine A 2B receptor activation: A mutational analysis of transmembrane domains 4 and 5 and the second extracellular loop","volume":"8","author":"Peeters","year":"2012","journal-title":"Purinergic Signal"},{"key":"B350","doi-asserted-by":"publisher","first-page":"6123","DOI":"10.1038\/s41467-025-59021-9","article-title":"Tumor site-directed A1R expression enhances CAR T cell function and improves efficacy against solid tumors","volume":"16","author":"Sek","year":"2025","journal-title":"Nat Commun"},{"key":"B351","doi-asserted-by":"publisher","first-page":"e002224","DOI":"10.1136\/jitc-2020-002224","article-title":"Intratumoral OH2, an oncolytic herpes simplex virus 2, in patients with advanced solid tumors: a multicenter, phase I\/II clinical trial","volume":"9","author":"Zhang","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B352","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.08.029","article-title":"Intercellular nanotube-mediated mitochondrial transfer enhances T cell metabolic fitness and antitumor efficacy","volume":"187","author":"Baldwin","year":"2024","journal-title":"Cell"},{"key":"B353","doi-asserted-by":"publisher","first-page":"e006728","DOI":"10.1136\/jitc-2023-006728","article-title":"Tryptophan depletion sensitizes the AHR pathway by increasing AHR expression and GCN2\/LAT1-mediated kynurenine uptake, and potentiates induction of regulatory T lymphocytes","volume":"11","author":"Solvay","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B354","doi-asserted-by":"publisher","first-page":"e008594","DOI":"10.1136\/jitc-2023-008594","article-title":"Novel anti-CD73-IL-2v bispecific fusion protein augments antitumor immunity by alleviating immunosuppressive adenosine pathways in CD8+ T cells","volume":"13","author":"Shin","year":"2025","journal-title":"J Immunother Cancer"},{"key":"B355","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3967","article-title":"Patient-derived xenografts undergo mouse-specific tumor evolution","volume":"49","author":"Ben-David","year":"2017","journal-title":"Nat Genet"},{"key":"B356","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-024-00706-6","article-title":"Cancer organoids 2.0: modelling the complexity of the tumour immune microenvironment","volume":"24","author":"Polak","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"B357","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann Oncol"},{"key":"B358","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s40425-019-0577-1","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B359","doi-asserted-by":"publisher","first-page":"e175824","DOI":"10.1172\/JCI175824","article-title":"FDA Modernization Act 2.0: transitioning beyond animal models with human cells, organoids, and AI\/ML-based approaches","volume":"133","author":"Zushin","year":"2023","journal-title":"J Clin Invest"},{"key":"B360","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-24-0042","article-title":"Precision endpoints for contemporary precision oncology trials","volume":"14","author":"Hoo","year":"2024","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676702\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:32:26Z","timestamp":1767875546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1676702\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":360,"alternative-id":["10.3389\/fimmu.2025.1676702"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1676702","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1676702"}}